Evercore ISI Rates Vaxcyte Inc. (PCVX) as an Overweight Following CDC Changes to Childhood Vaccination Recommendations [Yahoo! Finance]
Vaxcyte, Inc. (PCVX)
Company Research
Source: Yahoo! Finance
Vaxcyte Inc. (NASDAQ:PCVX), keeping a positive view as the company advances its vaccine pipeline on schedule. The firm expects topline results from the Phase 3 OPUS-1 trial in late 2026, with an adult BLA filing planned for 2027. It also noted progress in other studies: OPUS-2 has started dosing, OPUS-3 will begin in early 2026, and both should report results in 2027. Meanwhile, the infant Phase 2 VAX-31 study is on track, with key readouts expected by mid-2027. Earlier on January 6, Evercore ISI reiterated an Outperform rating on Vaxcyte Inc., impressed by the CDC's changes to childhood vaccination recommendations. The positive stance comes from the CDC removing blanket recommendations for several vaccines, including Flu, COVID-19, and Hepatitis B. In addition, recommendations for childhood vaccinations, such as measles, polio, tetanus, and HPV, among others, remain in place. The company is well-positioned to benefit, as it is also developing pneumococcal conjugate vaccines (
Show less
Read more
Impact Snapshot
Event Time:
PCVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PCVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PCVX alerts
High impacting Vaxcyte, Inc. news events
Weekly update
A roundup of the hottest topics
PCVX
News
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.MarketBeat
- Vaxcyte Announces Pricing of $550 Million Public Offering [Yahoo! Finance]Yahoo! Finance
- Vaxcyte Announces Pricing of $550 Million Public OfferingGlobeNewswire
PCVX
Earnings
- 11/4/25 - Miss
PCVX
Sec Filings
- 2/2/26 - Form 8-K
- 1/30/26 - Form 424B5
- 1/29/26 - Form 424B5
- PCVX's page on the SEC website